Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 in Healthy Adult Subjects
Conditions
Interventions
VX-993
Locations
1
United States
ICON Salt Lake City
Salt Lake City, Utah, United States
Start Date
July 26, 2024
Primary Completion Date
September 10, 2024
Completion Date
September 10, 2024
Last Updated
October 10, 2024
NCT07231419
NCT06382272
NCT07553000
NCT06821607
NCT07548385
NCT04577690
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions